



**PRESS RELEASE**

**Ticker Symbol: CUR**

**DIAGNOCURE'S GCC MARKER FOR THE STAGING OF COLORECTAL CANCER  
DISCUSSED AT TWO SCIENTIFIC MEETINGS  
First sales of the Previstage™ GCC test confirmed**

**QUEBEC CITY (Canada), September 25, 2008** – DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that its Guanylyl Cyclase C (GCC) marker for identifying colorectal cancer cells is being featured at two scientific meetings this month. The Company also announced that its wholly-owned subsidiary, DiagnoCure Oncology Laboratories, had received its first orders of its new Previstage™ GCC Colorectal Cancer Staging Test and is now delivering test results to physicians.

**GCC marker presented at major conferences**

The GCC marker, for which DiagnoCure owns exclusive worldwide diagnostic rights, is being featured in two scientific meetings this month. Dr. Scott Waldman, from Thomas Jefferson University, who first identified the relation of the GCC gene to colorectal cells, is presenting his research work and discussing the applications of molecular diagnostics to cancer management.

Dr. Waldman's work was recognized at this year's Molecular Diagnostics in Cancer Therapeutics Conference. This important conference is devoted to the latest developments in the integration of molecular diagnostics with cancer drug development and patient treatment. Aspects of GCC lymph node testing were presented to the attendees coming from the industry, academic institutions and the government, as well as patient-advocacy groups and regulatory agencies. Also, on September 24, as part of the same meeting, Dr. Waldman participated in a local media roundtable entitled Molecular Diagnostics: Leading the World from Philadelphia.

In addition, on September 29, at the Biomarker Discovery Summit, Dr. Waldman will be chairing and presenting selected GCC lymph node testing research data in a pre-conference workshop entitled: Novel Approaches to Cancer Biomarkers.

**First orders of Previstage™ GCC received**

Following on the research work of Dr. Waldman, DiagnoCure developed the Previstage™ GCC Colorectal Cancer Staging Test, and launched the test at the end of August 2008. The Company reports that physicians have started to order the test and are now sending lymph nodes removed during colorectal surgery to be tested with Previstage™ GCC for the presence of GCC. "This is a very positive first response to the launch of our test. For the moment, we have a small sales team focusing on educating the market and getting our first sales. We will continue to introduce Previstage™ GCC at meetings, present new data and expand the team as required. We are confident that our disciplined launch and management will help us achieve commercial success," stated John Schafer, President and CEO of DiagnoCure.

**About Previstage™ GCC**

Every year in North America, 174,000 people are diagnosed with colorectal cancer, and 142,000 colorectal cancer surgeries are performed. Staging a patient with colorectal cancer is crucial because it determines the patient's course of treatment after the surgery. Current standard of care requires that pathologists microscopically examine a thin slice of tissue from each of the lymph nodes harvested during the patient's surgery to see if cancer has spread. Currently, up to 25 - 30 percent of patients with no pathologically-positive lymph nodes (stage I and II cancers) later develop recurrent disease, presumably through occult metastases that have escaped detection. Most of these patients do not receive additional therapies such as chemotherapy. With a detection capacity that is close to 100,000 more sensitive than

